About

Leadership

Meet Our Leadership Team

Jay P. Shepard

Jay P. Shepard

Chief Executive Officer

Jay has more than 33 years of experience across pharmaceutical, biotechnology and drug delivery companies, most recently as President and Chief Executive Office of Versartis, where he was also a member of the Board of Directors. Previously, Jay was an Executive Partner at Sofinnova Ventures, a healthcare-focused venture capital firm, where he leveraged his industry expertise in support of the firm’s portfolio companies.
(more…)

Vinay Shah

Vinay Shah

Chief Financial Officer

Mr. Shah brings more than 16 years of financial management experience in the medical device and biopharmaceutical industries. Before joining Aravive, Mr. Shah was Executive Director of Finance and Strategy Analytics for Pacira Pharmaceuticals Inc., a specialty pharmaceutical company. (more…)

Gail McIntyre, PhD, DABT

Gail McIntyre, PhD, DABT

Senior Vice President, Research & Development

Dr. McIntyre has more than 25 years of experience in the drug discovery and development industry. She has authored more than 30 regulatory submissions and is a board-certified toxicologist with extensive experience in moving compounds through lead optimization and clinical development onto the market. (more…)

Laura Bonifacio, PharmD, PhD

Laura Bonifacio, PharmD, PhD

Vice President, Clinical Programs

Dr. Bonifacio brings more than 7 years of experience in drug development to Aravive Biologics. She spent 4 years at Furiex Pharmaceuticals, Inc and was responsible for managing an 11-study clinical pharmacology program and preparing the Clinical Pharmacology Summary for a late stage GI program that is now on the market in the US and EU. (more…)

Kevin Hass

Kevin Hass

Vice President, Finance

Kevin has more than 20 years of experience in the high tech and biotech industries combined, 15 years of which have most recently been in the biotech industry with both large commercial and small emerging companies. He joined Versartis as a consultant in December 2013, became the Corporate Controller in January 2014 prior to the Company’s IPO and served in that capacity until December 2017.  (more…)